Trial Profile

A phase 1 study evaluating safety, pharmacokinetic and pharmacodynamic single-ascending dose of OMS1029

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OMS 1029 (Primary) ; OMS 1029 (Primary)
Indications Wet age-related macular degeneration
Focus Adverse reactions

Most Recent Events

07 Aug 2024 Status changed from active, no longer recruiting to completed, according to a Omeros Corporation media release.
20 Mar 2023 New trial record
13 Mar 2023 According to a Omeros Corporation media release, dosing of all cohorts was successfully completed in early 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com